NDAORALTABLETPriority Review
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
7
Data completeness
5/8 — Partial
Priority Review
OJEMDA (tovorafenib) by Day One Biopharmaceuticals is type ii raf kinase inhibitors [moa]. Approved for low-grade glioma, pediatric low-grade glioma, raf-altered glioma. First approved in 2024.
Drug data last refreshed 19h ago
Mechanism of Action
Type II RAF Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications (3)
Worked on OJEMDA at Day One Biopharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.